左西孟旦治疗慢性心力衰竭患者的效果  

Effect of Levosimendan on Patients with Chronic Heart Failure

作　　者：初英虹[1] 邢艳秋[1] 张霞 李雪辉 陈焕芹[1] 王志浩[1] 宋一平 张珍[1] 凌明英[1] Chu Yinghong;Xing Yanqiu;Zhang Xia;Li Xuehui;Chen Huanqin;Wang Zhihao;Song Yiping;Zhang Zhen;Ling Mingying(Department of Geriatric Medicine,Qilu Hospital of Shandong University,Key Laboratory of Cardiovascular Proteomics of Shandong Province,Jinan Shandong 250012,China;Department of Cardiology,Rizhao Central Hospital,Rizhao Shandong 276800,China)

机构地区：[1]山东大学齐鲁医院老年医学科·山东省心血管疾病蛋白质组学重点实验室,山东济南250012 [2]日照市中心医院心内科,山东日照276800

出　　处：《医疗装备》2020年第14期5-7,共3页Medical Equipment

基　　金：国家自然科学基金面上项目(81570356);山东省重点研发计划项目(2017GSF218014)。

摘　　要：目的探讨左西孟旦治疗慢性心力衰竭患者的效果。方法选取2013年1-12月于山东大学齐鲁医院心内科住院的77例患者,随机分为试验组(40例)和对照组(37例)。对照组给予常规治疗,试验组在对照组基础上加用左西孟旦治疗,比较两组临床有效率及治疗前后的血清氨基末端脑利钠肽前体(NT-proBNP)和肽素(Copeptin)水平变化情况。结果试验组临床有效率为89.2%,对照组为62.5%,差异有统计学意义(P<0.05)。治疗72 h后,试验组与对照组的Copeptin分别下降了(634.49±485.01)pg/ml和(328.78±261.25)pg/ml(P<0.05),NT-proBNP分别下降了(2 097.85±840.68)pg/ml和(1 375.77±879.07)pg/ml(P<0.05),试验组2个指标下降幅度均大于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论左西孟旦可明显降低慢性心力衰竭患者的血清Copeptin和NT-ProBNP水平,缓解患者的症状和体征。Objective To investigate the effect of levosimendan on patients with chronic heart failure.Methods From January to December 2013, 77 patients hospitalized in the Department of Cardiology, Qilu Hospital of Shandong University were randomly divided into experimental group(40 cases) and control group(37 cases).The control group were treated with conventional treatment, and the experimental group were treated with levosimendan on the basis of conventional treatment.The serum Copeptin concentration and ammonia N-terminal brain natriuretic peptide precursor(NT-proBNP) levels before and 72 hours after treatment of two groups were compared, and the overall clinical status were observed.Results The overall clinical status rate was 89.2% in the experimental group and 62.5% in the control group, the difference was statistically significant(P<0.05).After treatment, the blood Copeptin levels in the experimental group and the control group decreased by(634.49±485.01) pg/ml and(328.78±261.25) pg/ml, respectively(P<0.05).After treatment, NT-proBNP decreased by(2 097.85±840.68) pg/ml and(1 375.77±879.07) pg/ml, respectively(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion Levosimendan can reduce the serum levels of Copeptin and NT-proBNP in patients with chronic heart failure, relieve the symptoms and signs of patients.

关 键 词：心力衰竭 左西孟旦 血清氨基末端脑利钠肽前体 肽素 

分 类 号：R541.61[医药卫生—心血管疾病]